Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.10.0.1
Collaboration and License Agreements - Additional Information (Detail) - Novartis [Member] - USD ($)
1 Months Ended
Dec. 31, 2016
Jul. 05, 2017
Feb. 15, 2017
Collaboration Agreement [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Proceeds from option exercised   $ 7,000,000  
Maximum milestone payments to be received upon achievement of certain milestones $ 650,000,000    
Percentage of observational study costs 50.00%    
Assumed percentage of observational study costs upon completion of ongoing Phase 2b trails 100.00%    
Required prior written notice period for termination of collaboration agreement 180 days    
Percentage of reduction in milestone and royalty payments 50.00%    
Collaboration Agreement [Member] | Upfront Payment [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Non-refundable payment received $ 50,000,000    
Investment Agreement [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Debt instrument, maximum borrowing capacity $ 15,000,000    
Debt instrument, interest rate 6.00%    
Debt instrument, maturity date Dec. 31, 2019    
Debt instrument, conversion price percentage 120.00%    
Number of days trailing average closing price of common stock immediately prior to the conversion date 20 days    
Maximum percentage of outstanding shares will receive upon debt instrument conversion 19.00%    
Investment Agreement [Member] | Convertible Promissory Note [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Promissory note, principal amount     $ 15,000,000